HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.2%

Neg 0% Neu 88.2% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.